5Prevention of damage induced by aspirin in the GI tract
Introduction
The mechanism of aspirin related GI toxicity as well as its epidemiology has been well described in previous chapters in this book. At low-dose (325 mg or less) aspirin predominantly inhibits the cyclooxygenase (COX)-1 isoform in the GI mucosa leading to ulcerogenic effects. Aspirin can also promote bleeding from pre-existing lesions in the GI tract, such as tumours or diverticulae due to impaired platelet function. Higher doses of aspirin have considerable dose related toxicity along despite potent analgesic properties, and have been largely abandoned in clinical practice due to the development of less toxic NSAIDs with more favourable risk benefit profiles. This chapter will focus on the data on strategies to reduce low-dose aspirin risk to the GI tract. The major focus will be on upper GI ulceration and bleeding. Injury to the small bowel and what little we know about strategies to reduce it will be touched upon as well.
There are no known strategies to reduce the risk of aspirin related haemorrhage due to its antiplatelet effect leading to bleeding from an effect on a pre-existing lesion. Anecdotally, this can be of potential benefit as well as harm, for example early detection of an early colon cancer due to presentation with overt bleeding when aspirin is initiated for cardiovascular therapy. Restricting aspirin use to only those patients in whom the benefits exceed its risk, such as secondary prevention of CV events and those with elevated CV risk for primary prevention is a key strategy to limit aspirin’s GI adverse events [1]. Although debated, the lowest effective aspirin dose (75–81 mg) can minimize GI side effects compared to higher doses; these and other strategies such as Helicobacter Pylori eradication are discussed in detail by other authors in this monograph.
Section snippets
Gastroprotective agents
Although somewhat less well studied than full dose NSAID therapy, strategies to reduce ulcers and bleeding from low-dose aspirin have been evaluated in endoscopic as well as outcome studies, both observational as well as randomized controlled trials. Key studies in each category will be reviewed to support existing evidence based recommendations for therapy.
As prostaglandin depletion is the central mechanism for ulcer development due to COX inhibitors, replacement therapy with the synthetic
Conflict of interest statement
Dr Scheiman is a consultant to Astra-Zeneca, Novartis and Pozen, Inc.
References (30)
- et al.
Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis
Clin Ther
(2004) - et al.
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomized, double-blind, placebo-controlled trial
Lancet
(2009 Jul 11) - et al.
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions
Gastroenterology
(2010 Jan) - et al.
Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy
Gastroenterology
(2011 Jul) - et al.
Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study
Gastroenterology
(2003 Mar) - et al.
Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment
Clin Gastroenterol Hepatol
(2009 May) - et al.
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
Lancet
(2009 May 30) - et al.
Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury
Aliment Pharmacol Ther
(2000) - et al.
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
Ann Intern Med
(1995 Aug 15) - et al.
Omeprazole ameliorates aspirin-induced gastroduodenal injury
Dig Dis Sci
(1994)
Protective effect of omeprazole against low-dose acetylsalicylic acid. Endoscopic controlled double-blind study in healthy subjects
Arzneimittelforschung
Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind study
Arzneimittelforschung
Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin
Am J Gastroenterol
Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomized, controlled trial (OBERON)
Heart
Cited by (15)
Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review
2020, Journal of ArthroplastyCitation Excerpt :It is well-established that long-term aspirin treatment is associated with GI bleeding and ulceration [73–75], but studies have found that the risk of gastrotoxicity is dose-related [75,76] and GI bleeding is more strongly related to the dose of aspirin than the duration of treatment [73]. Low doses of aspirin decrease the synthesis of the platelet aggregating agent thromboxane A2 [67] via irreversibly inhibiting cyclooxygenase-1 [77]. However, high doses of aspirin suppress prostacyclin metabolism [67] by irreversibly inhibiting cyclooxygenase-2, which is associated with inflammatory mediators [78].
Aspirin: The balance between benefits and harms
2012, Best Practice and Research: Clinical GastroenterologyWarfarin versus aspirin in heart failure and sinus rhythm [1]
2012, New England Journal of MedicineNoncoding RNA Roles in Pharmacogenomic Responses to Aspirin: New Molecular Mechanisms for an Old Drug
2021, BioMed Research InternationalGastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus
2017, World Journal of GastroenterologyInfluence of drugs on smelling capacity. A review
2017, Flavour and Fragrance Journal